US11130956B2ActiveUtilityA1
Reducing the toxicity of agrobacterium endotoxin
Est. expiryJun 5, 2037(~10.9 yrs left)· nominal 20-yr term from priority
C12N 9/1029C12P 19/12A61K 2039/55572A61K 39/39C12N 15/8205C07K 14/195C12N 15/8258C12N 2710/00023C12P 19/04C12N 15/743
49
PatentIndex Score
0
Cited by
53
References
12
Claims
Abstract
The present invention relates to the fields of genetically modified Agrobacterium strains, vaccine adjuvants, and generally molecular biology and immunology. Provided herein are modified Agrobacterium strains that produce lipopolysaccharide (LPS) having reduced toxicity or detoxified lipopolysaccharide, and methods of obtaining such strains for plant-based production of biologies. Also provided herein are uses of reduced or detoxified LPS as adjuvants suitable for clinical use.
Claims
exact text as granted — not AI-modifiedWe claim:
1. A genetically modified strain of Agrobacterium , wherein the genetically modified strain comprises a functional deletion of one or more polypeptides required for synthesis of Very Long Chain Fatty Acid (VLCFA) and is deficient in Lipopolysaccharide (LPS) toxicity relative to its parent strain;
wherein the functional deletion is achieved by removal of at least a portion of the gene encoding AcpXL-dependent lipid A acyltransferase (lpxXL) and at least a portion of the gene encoding Acyl carrier protein (acpXL), and
wherein the genetically modified strain comprises an exogenous nucleic acid encoding Lipid A 4′-phosphatase (LpxF), and
wherein the genetically modified bacterium retains the ability to mediate T-DNA transfer into plant cells, and to mediate T-DNA insertion into a plant cell genome.
2. The modified strain of claim 1 , wherein the modified strain produces tetra-acylated lipid A lacking VLCFA.
3. The modified strain of claim 1 , wherein the modified strain produces penta-acylated lipid A with VLCFA replaced by a 16:0 acyl chain or 18:1 acyl chain.
4. The modified strain of claim 1 , wherein the modified strain produces a mixture of tetra- and penta-acylated lipid A.
5. The modified strain of claim 1 , wherein the parent strain is A. tumefaciens GV3101 or A. tumefaciens LBA4404.
6. The modified strain of claim 1 , wherein the parent strain is A. tumefaciens strain C58.
7. A method or reducing Lipopolysaccharide (LPS) toxicity in an Agrobacterium bacterium, the method comprising: deleting or disrupting at least a portion of a gene encoding AcpXL-dependent lipid A acyltransferase (IpxXL) and at least a portion of a gene encoding Acyl carrier protein (acpXL) in the bacterium, wherein the deletion or disruption comprises a functional deletion;
introducing an exogenous nucleic acid encoding Lipid A 4′-phosphatase (LpxF) into the bacterium; whereby a genetically modified Agrobacterium is obtained;
wherein the genetically modified Agrobacterium exhibits lower LPS toxicity than an unmodified Agrobacterium , and
wherein the genetically modified Agrobacterium retains the ability to mediate T-DNA transfer into plant cells, and to mediate T-DNA insertion into a plant cell genome.
8. The method of claim 7 , wherein the Agrobacterium bacterium is Agrobacterium tumefaciens strain GV3101 or LBA4404.
9. The method of claim 7 , wherein the Agrobacterium bacterium is Agrobacterium tumefaciens strain C58.
10. A method for generating a LPS variant molecule having reduced endotoxicity and improved immunogenicity, the method comprising the steps of:
(a) providing the modified Agrobacterium strain of claim 1 ;
(b) allowing the modified Agrobacterium strain to grow under conditions to produce a LPS variant molecule having reduced endotoxicity and improved immunogenicity compared to an LPS molecule relative to its parent strain.
11. A lipopolysaccharide (LPS) isolated from a genetically modified Agrobacterium of claim 1 , wherein the LPS exhibits reduced toxicity relative to LPS produced by a wild-type Agrobacterium or an Agrobacterium that is not so genetically modified.
12. An adjuvant comprising an immunostimulatory quantity of the reduced toxicity LPS of claim 11 and a pharmaceutically acceptable carrier.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.